ABSTRACT
The effect of heart-type fatty acid binding protein [H-FABP] remains unclear on the quality of the prognoses of patients with acute coronary syndrome [ACS]. The authors searched the EMBASE, PubMed, Cochrane Library, and Medline electronic databases from their respective inceptions throughout June 2017. Odds ratios were pooled from individual studies, and conducted heterogeneity analysis, quality assessment, and publication bias analysis. A total of four studies with 1,994 patients were included [554 positive patients; 1,440 negative patients]. Pooled analysis of these studies showed that patients positive for H-FABP had higher incidence for mortality [OR, 6.39; p <0.01] and cardiac events [OR, 3.94; P<0.01] than negative patients, but myocardial infarction [MI] [OR, 1.43; P=0.32] showed no significant differences. ACS patients positive for H-FABP had higher rates in cardiac events and mortality. The incidence of MI showed no significant difference, possibly because this study was based on limited data from randomized studies. Additional substantial randomized controlled trials certainly needed to verify these discovery